Published in World Psychiatry on October 01, 2003
Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. Neuroreport (2008) 1.24
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) (2009) 1.14
Neuropeptides in depression: role of VGF. Behav Brain Res (2008) 0.97
Association of rare variation in the glutamate receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia. Eur J Hum Genet (2014) 0.94
Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res (2009) 0.93
The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry (2010) 0.91
Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl) (2012) 0.90
The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig (2010) 0.89
Thalamic volumes in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2010) 0.89
Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther (2010) 0.87
The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol (2014) 0.86
Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis. Nat Med (2016) 0.86
Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology (2014) 0.85
Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J Psychiatry Neurosci (2014) 0.81
Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord (2013) 0.81
On the Teneurin track: a new synaptic organization molecule emerges. Front Cell Neurosci (2015) 0.81
Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies. Neurosci Biobehav Rev (2015) 0.77
Differential expression of transcriptional regulatory units in the prefrontal cortex of patients with bipolar disorder: potential role of early growth response gene 3. Transl Psychiatry (2016) 0.76
The enzymatic activities of brain catechol-O-methyltransferase (COMT) and methionine sulphoxide reductase are correlated in a COMT Val/Met allele-dependent fashion. Neuropathol Appl Neurobiol (2015) 0.75
Characterization of the early CNS stress biomarkers and profiles associated with neuropsychiatric diseases. Curr Genomics (2012) 0.75
Delay in the recovery of normal sleep-wake cycle after disruption of the light-dark cycle in mice: a bipolar disorder-prone animal model? Psychiatry Investig (2014) 0.75
[Bipolar disorder in childhood and adolescence]. Rev Bras Psiquiatr (2004) 0.75
Preclinical Evidences for an Antimanic Effect of Carvedilol. Neural Plast (2015) 0.75
(1)H-NMR, (1)H-NMR T2-edited, and 2D-NMR in bipolar disorder metabolic profiling. Int J Bipolar Disord (2017) 0.75
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 12.18
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Emergent properties of networks of biological signaling pathways. Science (1999) 9.93
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci (2000) 9.12
Protein kinase C and lipid signaling for sustained cellular responses. FASEB J (1995) 6.80
Stress and hippocampal plasticity. Annu Rev Neurosci (1999) 6.31
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
Protein kinase C: structure, function, and regulation. J Biol Chem (1995) 5.55
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci (2002) 5.17
Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry (2000) 4.99
Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 4.00
Neuroimaging studies of mood disorders. Biol Psychiatry (2000) 3.92
Complexity in biological signaling systems. Science (1999) 3.05
Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A (2001) 3.01
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav (1997) 2.67
Molecular targets of lithium action. Annu Rev Pharmacol Toxicol (2001) 2.63
PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry (1999) 2.48
Lithium-induced increase in human brain grey matter. Lancet (2000) 2.31
Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron (1999) 2.30
Enhancement of hippocampal neurogenesis by lithium. J Neurochem (2000) 2.28
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry (2000) 2.25
The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem (1999) 2.20
The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem (1999) 2.04
Protein kinase C. Pharmacol Ther (1991) 1.99
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci (2000) 1.86
Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem (1999) 1.77
The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem (2001) 1.73
Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry (2002) 1.70
Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord (2001) 1.68
Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry (1999) 1.66
Transient changes in mesolimbic dopamine and their association with 'reward'. J Neurochem (2002) 1.59
Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol (1992) 1.55
Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem (2002) 1.55
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry (2000) 1.55
Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry (1996) 1.53
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry (2000) 1.53
Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry (2001) 1.53
Molecular machines integrate coincident synaptic signals. Cell (1993) 1.51
Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology (2000) 1.49
N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol (1995) 1.47
Episodic tardive dyskinesia and parkinsonism in bipolar disorder patients. Can J Psychiatry (1993) 1.43
Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett (2002) 1.39
Synaptic plasticity and mood disorders. Mol Psychiatry (2002) 1.38
Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry (1999) 1.30
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry (1999) 1.20
Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry (2000) 1.18
Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry (2000) 1.17
Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann N Y Acad Sci (1996) 1.16
Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry (1998) 1.13
Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry (1993) 1.08
Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull (2002) 1.07
A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry (2000) 1.06
Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry (2001) 1.04
PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry (2002) 1.03
PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry (2002) 1.03
Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry (1996) 1.03
Serotonin type-1A receptor imaging in depression. Nucl Med Biol (2000) 1.01
Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar disorder patients and matched healthy control volunteers. Psychol Med (2002) 1.00
Neuropathology of bipolar disorder. Biol Psychiatry (2000) 1.00
The nature of bipolar disorder. J Clin Psychiatry (2000) 0.97
High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry (2000) 0.96
Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord (1999) 0.96
Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry (2000) 0.94
Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry (1999) 0.93
Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry (1994) 0.93
Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder. Biol Psychiatry (2001) 0.91
Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry (1992) 0.91
Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging (1995) 0.91
Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem (1993) 0.90
G proteins: implications for psychiatry. Am J Psychiatry (1992) 0.89
Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery (1993) 0.88
Cholinergic sensitivity predicts severity of mania. Psychiatry Res (2000) 0.86
High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. Am J Psychiatry (1997) 0.84
Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry (1999) 0.84
Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am J Med Genet (1998) 0.84
Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord (2000) 0.83
Antidegenerative effects of Mg(2+)-valproate in cultured cerebellar neurons. Funct Neurol (1996) 0.83
Abnormal G protein alpha(s) - and alpha(i2)-subunit mRNA expression in bipolar affective disorder. Mol Psychiatry (1998) 0.82
Antidepressant treatments in the 21st century. Biol Psychiatry (1998) 0.82
Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs. Neuropsychobiology (2001) 0.81
Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. Psychoneuroendocrinology (1995) 0.81
Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology (1999) 0.81
Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. Arch Gen Psychiatry (1995) 0.79
Pupillary cholinergic sensitivity to pilocarpine increases in manic lithium responders. Biol Psychiatry (1999) 0.79
No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder. Arch Gen Psychiatry (1997) 0.78
d-fenfluramine-induced prolactin responses in mania: evidence for serotonergic subsensitivity. Am J Psychiatry (1996) 0.78
Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium. Br J Psychiatry (2000) 0.78
The role of dopamine in rewarded behavior: ability, insight, drive or incentive? Pol J Pharmacol Pharm (1992) 0.77
Dopaminergic-cholinergic interactions in the striatum. Jpn J Psychiatry Neurol (1991) 0.76
Prolactin and cortisol responses to fenfluramine challenge in mania. Biol Psychiatry (1996) 0.76
[Disappearance of akinesia in Parkinson disease during a manic attack]. Rev Neurol (Paris) (1993) 0.76
Sumatriptan-induced growth hormone release in patients with major depression, mania, and normal controls. Neuropsychopharmacology (1997) 0.76
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Identification and replication of a combined epigenetic and genetic biomarker predicting suicide and suicidal behaviors. Am J Psychiatry (2014) 1.73
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
Doubly randomized delayed-start design for enrichment studies with responders or nonresponders. J Biopharm Stat (2012) 1.55
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry (2012) 1.27
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry (2003) 1.25
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology (2010) 1.24
A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder. Am J Psychiatry (2012) 1.21
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
Genome-wide linkage and follow-up association study of postpartum mood symptoms. Am J Psychiatry (2009) 1.21
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Depression: is pregnancy protective? J Womens Health (Larchmt) (2012) 1.16
Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage (2010) 1.16
Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. Hum Brain Mapp (2012) 1.14
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2008) 1.13
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry (2004) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol (2009) 1.12
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry (2012) 1.12
Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci (2003) 1.11
McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2010) 1.11
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry (2012) 1.09
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08
Letter to the editor in response to 2012 article by Frances and Jones. Bipolar Disord (2014) 1.07
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol (2012) 1.06
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry (2012) 1.05
Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety (2013) 1.05
Performance on a virtual reality spatial memory navigation task in depressed patients. Am J Psychiatry (2007) 1.03
Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.03
A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry (2008) 1.02
Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry (2013) 1.02
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry (2014) 1.00
Defining anxious depression: a review of the literature. CNS Spectr (2013) 0.99
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98
Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry (2004) 0.98
Neurobiology of bipolar disorder. Expert Rev Neurother (2008) 0.97
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans. Biol Psychiatry (2009) 0.95
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord (2012) 0.95
Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord (2013) 0.95
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety (2013) 0.95
Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. Neuroimage (2012) 0.94
New therapeutic targets for mood disorders. ScientificWorldJournal (2010) 0.94
Major depression is not associated with blunting of aversive responses; evidence for enhanced anxious anticipation. PLoS One (2013) 0.94
Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord (2003) 0.93
A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord (2008) 0.93
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) (2014) 0.93
Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry (2013) 0.93
Hot and cold cognition in unmedicated depressed subjects with bipolar disorder. Bipolar Disord (2009) 0.93
Neurobiology of anxious depression: a review. Depress Anxiety (2013) 0.93
Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol (2010) 0.92
The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry (2010) 0.91